Philips has partnered with cardiac MR software developer Myocardial Solutions to identify heart disease due to cardiotoxicity in cancer survivors and patients undergoing cancer therapies.
The collaboration aims to improve survival rates and bridge a gap between heart and cancer care, Philips said. A combination of the MRI acquisition sequence Fast-SENC, the MyoStrain analysis tool, and Philips’ SmartSpeed and BlueSeal technologies will be used to rapidly identify asymptomatic patients at risk of heart failure.
With the combination, early dysfunction of heart failure can be detected across 48 segments of the heart in 10 minutes, with less than five minutes of analysis time to help identify regional dysfunction before it impacts the entire heart, according to Philips.
Myocardial Solutions is based in Durham, NC. In November 2024, the company received clearance from the U.S. Food and Drug Administration (FDA) for the latest version of its MyoStrain software.